Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy
Sara Saberi(Michigan Medicine), Daniel Jacoby(Baim Institute for Clinical Research), Amy J. Sehnert, Nuno Cardim, Benjamin Meder(Heidelberg University), Christopher M. Kramer(American College of Cardiology), Anjali Owens(University of Pennsylvania), Tim Seidler(University of Göttingen), Mark V. Sherrid(NYU Langone Health), Neal K. Lakdawala(Brigham and Women's Hospital), Michael Jerosch‐Herold(Brigham and Women's Hospital), Mohamad H. Yamani(Jacksonville College), Ahmad Masri(Oregon Health & Science University), Jeanette Schulz‐Menger(Max Delbrück Center), Farbod Sedaghat‐Hamedani(Universität Ulm), Raymond Y. Kwong(Brigham and Women's Hospital), Andrew Wang(Duke University Hospital), Ofer Havakuk(Tel Aviv University), Victoria Florea(Fauna and Flora International), Wanying Li
Cited by 234
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing
|Journal of Cardiovascular Magnetic Resonance|2013|1.5k
Current and Evolving Echocardiographic Techniques for the Quantitative Evaluation of Cardiac Mechanics: ASE/EAE Consensus Statement on Methodology and Indications
|Journal of the American Society of Echocardiography|2011|1.2k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Criteria for Evaluation of Novel Markers of Cardiovascular Risk
|Circulation|2009|1.1k